Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The recent failure of the T-cell-based HIV vaccine trial led by Merck & Co., Inc. prompts the urgent need to refocus on the question of which T-cell responses are required to control HIV replication. The well-described association between the expression of particular MHC class I molecules and successful containment of HIV or, in the macaque model, SIV replication provide a valuable starting point from which to evaluate more precisely what might constitute effective CD8(+) T-cell responses. Here, we review recent studies of T-cell-mediated control of HIV and SIV infection, and offer insight for the design of a successful T-cell-based HIV vaccine in the future.

Original publication

DOI

10.1038/nri2357

Type

Journal article

Journal

Nat Rev Immunol

Publication Date

08/2008

Volume

8

Pages

619 - 630

Keywords

AIDS Vaccines, Animals, CD8-Positive T-Lymphocytes, HIV Infections, HIV-1, Histocompatibility Antigens Class I, Humans, Macaca mulatta, SAIDS Vaccines, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Virus Replication